Work

Consider brexpiprazole for agitation in Alzheimer’s disease, with new therapies under investigation for agitation and psychosis

Year: 2026

Type: article

Abstract: Agitation and psychosis are common, highly challenging symptoms of Alzheimer’s disease (AD). Although non-pharmacological strategies are the recommended first-line treatment for agitation and psychosis in AD, pharmacological interventions may be necessary if there is severe risk of self-harm or harm to others. Brexpiprazole is approved by the US FDA for treatment of agitation associated with dementia due to AD, while other medications are used off label. Several novel and repurposed drugs are under investigation for use in agitation and psychosis in AD.

Source: Drugs & Therapy Perspectives

DOI: 10.1007/s40267-026-01223-2

Authors: Thomas B. Burgess, Simon Fung

Institution: Springer Nature (New Zealand)

Language: English

Topic: Dementia and Cognitive Impairment Research

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,490